低频超声波用于肺高血压治疗
Vytautas Ostasevicius1, Vytautas Jurenas2, Mantas Venslauskas2
1Institute of Mechatronics, Kaunas University of Technology, Studentu Street 56, 51424, Kaunas, Lithuania. vytautas.ostasevicius@ktu.lt.
Respiratory research
|February 5, 2024
概括
低频超声波显示出治疗肺动脉高血压 (PAH) 的前景. 这种非侵入性治疗改善了血中的氧气水平,并降低了PAH的羊模型中的脉冲率和血压.
科学领域:
- 生物医学工程 生物医学工程
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
背景情况:
- 缺乏用于肺动脉高血压 (PAH) 的非侵入性治疗工具.
- 需要创新的治疗方法来支持PAH患者.
研究的目的:
- 为PAH治疗引入一种新型的低频超声波装置.
- 在临床前模型中评估该设备的治疗潜力.
主要方法:
- 开发了一种独特的低频超声波传感器,具有深层组织透能力.
- 为诱导的肺高血压建立一个羊模型.
- 监测关键的生理参数:血液中的氧气度,脉率和肺血压.
主要成果:
- 低频超声波暴露显著改变了绵羊的生理参数.
- 观察到,在7分钟的时间内,血液中氧和度 (SpO2) 增加了10%.
- 在7分钟内,脉率下降了10%,血压下降了13%.
结论:
- 低频超声波证明了肺高血压治疗的疗效.
- 这些发现提供了关于肺气交换和超声波治疗的生理效应的见解.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167
Pulmonary Hypertension: Classification and Pathogenesis
180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
180
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
182
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
182
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
158
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
158
Ultrasound II: Endoscopic Ultrasound and FibroScan
107
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
107
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165


